[8-K] IQVIA HOLDINGS INC. Reports Material Event

Rhea-AI Filing Summary

IQVIA Holdings Inc. appointed William G. Kaelin Jr., M.D. to its Board of Directors on November 5, 2025. The Board determined that Dr. Kaelin meets the New York Stock Exchange definition of an independent director. In connection with the appointment, he is expected to enter into the company’s standard indemnification agreement for non-management directors and will participate in the non-employee director compensation program described under “Director Compensation” in the proxy statement dated February 28, 2025. The company announced the appointment via a press release attached as Exhibit 99.1.

false 0001478242 0001478242 2025-11-05 2025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

IQVIA HOLDINGS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-35907		27-1341991
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2400 Ellis Rd.,

Durham, North Carolina 27703

(Address of principal executive offices)

Registrant’s telephone number, including area code: (919) 998-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on which Registered
Common Stock, par value $0.01 per share		“IQV”		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors (the “Board”) of IQVIA Holdings Inc. (the “Company”) appointed William G. Kaelin Jr., M.D. to the Board on November 5, 2025. The Board determined that Dr. Kaelin satisfies the New York Stock Exchange definition of “independent director.”

In connection with his appointment to the Board, Dr. Kaelin is expected to enter into the Company’s standard indemnification agreement with non-management directors, a copy of which is filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on October 3, 2016 and is incorporated herein by reference. Dr. Kaelin will participate in the non-employee director compensation arrangements established by the Company for non-employee directors, as described under “Director Compensation” in the Company’s proxy statement dated February 28, 2025, for its 2025 annual meeting of stockholders.

Item 7.01. Regulation FD Disclosure.

The Company issued a press release announcing the appointment of Dr. Kaelin, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press release dated November 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 5, 2025

IQVIA HOLDINGS INC.
By:		/s/ Eric Sherbet
		Eric Sherbet
		Executive Vice President, General Counsel and Secretary

FAQ

Who did IQV (IQVIA Holdings Inc.) appoint to its board?

The company appointed William G. Kaelin Jr., M.D. to the Board of Directors.

When was Dr. Kaelin appointed to IQVIA’s board?

He was appointed on November 5, 2025.

Is Dr. Kaelin considered independent under NYSE rules?

Yes. The Board determined he satisfies the NYSE definition of an independent director.

What compensation will Dr. Kaelin receive as a director of IQV?

He will participate in the non-employee director compensation arrangements described in IQVIA’s proxy statement dated February 28, 2025.

Will Dr. Kaelin sign an indemnification agreement with IQVIA?

He is expected to enter into the company’s standard indemnification agreement for non-management directors.

Did IQVIA issue a press release about the appointment?

Yes. A press release announcing the appointment is attached as Exhibit 99.1.

Where is IQVIA’s common stock listed and what is the ticker?

IQVIA’s common stock trades on the New York Stock Exchange under the ticker IQV.